Premium
Glutathione transferase P1‐1 as an arsenic drug‐sequestering enzyme
Author(s) -
Parker Lorien J.,
Bocedi Alessio,
Ascher David B.,
Aitken Jade B.,
Harris Hugh H.,
Lo Bello Mario,
Ricci Giorgio,
Morton Craig J.,
Parker Michael W.
Publication year - 2017
Publication title -
protein science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.353
H-Index - 175
eISSN - 1469-896X
pISSN - 0961-8368
DOI - 10.1002/pro.3084
Subject(s) - glutathione , chemistry , gstp1 , dimer , active site , arsenic , phenylarsine oxide , enzyme , biochemistry , mutagenesis , stereochemistry , organic chemistry , mutation , gene
Abstract Arsenic‐based compounds are paradoxically both poisons and drugs. Glutathione transferase (GSTP1‐1) is a major factor in resistance to such drugs. Here we describe using crystallography, X‐ray absorption spectroscopy, mutagenesis, mass spectrometry, and kinetic studies how GSTP1‐1 recognizes the drug phenylarsine oxide (PAO). In conditions of cellular stress where glutathione (GSH) levels are low, PAO crosslinks C47 to C101 of the opposing monomer, a distance of 19.9 Å, and causes a dramatic widening of the dimer interface by approximately 10 Å. The GSH conjugate of PAO, which forms rapidly in cancerous cells, is a potent inhibitor ( K i = 90 n M ) and binds as a di‐GSH complex in the active site forming part of a continuous network of interactions from one active site to the other. In summary, GSTP1‐1 can detoxify arsenic‐based drugs by sequestration at the active site and at the dimer interface, in situations where there is a plentiful supply of GSH, and at the reactive cysteines in conditions of low GSH.